COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 1 FDA record to the applicant name Biocartis Us, Inc.. It includes 1 original PMA approval. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 15, 2025 to Aug 15, 2025. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code SFL appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P250005, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: Two Pierce Pl., Suite 1510, Itasca, IL, 60174. Recorded on P250005, decision dated Aug 15, 2025.
Device categories in this collection
Nucleic Acid Based Assay, Microsatellite Instability.
Changes described in PMA records
FDA’s recorded scope: For in vitro diagnostic use. For Prescription Use Only. For use on the Biocartis Idylla System only.The Idylla CDx MSI Test is an in vitro diagnostic test intended for the qualitative detection of a panel of seven monomorphic biomarkers (ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A and SULF2) for identification of microsatellite instability (MSI) in colorectal cancer (CRC) tissue. The Idylla CDx MSI Test uses formalin-fixed, paraffin embedded (FFPE) tissue sections from patients with CRC, from which nucleic acids are extracted, then analyzed using PCR amplification and subsequent melt-curve analysis. The Idylla CDx MSI Test reports MSI status as either Microsatellite Stable (MSS) or Microsatellite Instability-High (MSI-H) or invalid. The test is intended as a companion diagnostic to identify CRC patients with MSI-H status, who may benefit from treatment with OPDIVO (nivolumab) as a monotherapy and/or treatment with OPDIVO (nivolumab) in combination with YERVOY (ipilimumab).
Aug 15, 2025Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.